Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$15.18M-$15.18MN/M vs Q2 2022 EPS Diluted-$0.58-$0.58N/M vs Q2 2022 Operating Income-$15,642,000N/M Operating Cash Flowderived-$13,643,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,690,000N/M ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end